Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2021 | $16.00 → $13.00 | Buy | Chardan Capital |
| 10/19/2021 | $28.00 → $16.00 | Buy | Chardan Capital |
| 10/18/2021 | $20.00 → $10.00 | Buy | HC Wainwright & Co. |
8-K - BiomX Inc. (0001739174) (Filer)
DEF 14A - BiomX Inc. (0001739174) (Filer)
8-K - BiomX Inc. (0001739174) (Filer)
4 - BiomX Inc. (0001739174) (Issuer)
4 - BiomX Inc. (0001739174) (Issuer)
3 - BiomX Inc. (0001739174) (Issuer)
Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously
Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously
HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously
NETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced that it has entered into an option agreement to acquire control of DFSL, a developer of proprietary LADAR (Laser Radar)–based detection systems for security, defense, and critical infrastructure applications. DFSL's LADAR technology combines laser-based sensing with proprietary AI algorithms to detect and respond to both UAV and ground-based intruders. BiomX intends to exercise the option subject to the closing of the underlying agreement and obtaining shareholder approval as necessary or consideration consisting of a combination of cash, promissory note, shares of common stock and warrants. Separat
NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board. Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200
NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the "Company Guide"), requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity
NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board. Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200
Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance
NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se
Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a conference call and webcast today at 8:30 AM ET NESS ZIONA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specif
NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its third quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and a live audio webcast at 8:30 a.m. ET, to discuss the third quarter of 2025 financial results and provide program updates. To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the sta
SC 13G/A - BiomX Inc. (0001739174) (Subject)
SC 13G/A - BiomX Inc. (0001739174) (Subject)
SC 13G/A - BiomX Inc. (0001739174) (Subject)